A Double-blind, randomized, placebo-controlled multi-center, Phase II parallel dose-ranging study to assess the antifibrotic activity of G1262570 in chronic hepatitis C subjects with hepatic fibrosis (2006-2007)
Experts
Professor
Barbara Leggett
ATH - Professor
Royal Brisbane Clinical Unit
Faculty of Health, Medicine and Behavioural Sciences
